MiniMed announces pricing of initial public offering

Rhea-AI Summary

MiniMed Group (planned Nasdaq: MMED) priced an initial public offering of 28,000,000 shares at $20.00 per share, with expected Nasdaq trading to begin March 6, 2026 and closing of the offering expected March 9, 2026, subject to customary conditions.

MiniMed granted underwriters a 30-day option for up to 4,200,000 additional shares. Upon completion, Medtronic is expected to retain approximately 90.03% ownership (88.70% if the over-allotment is fully exercised). Proceeds will fund general corporate purposes and may repay intercompany debt to Medtronic.

Positive

• IPO size of 28,000,000 shares priced at $20.00
• Underwriter over-allotment option of 4,200,000 shares provides pricing flexibility
• Medtronic retains majority control (~90.03% ownership), supporting continuity

Negative

• Limited public float (~9.97% public ownership, 11.30% if over-allotment), which may reduce liquidity
• Portion of proceeds earmarked to repay intercompany debt to Medtronic, limiting growth capital

Key Figures

IPO shares offered: 28,000,000 shares IPO price: $20.00 per share Over-allotment shares: 4,200,000 shares +5 more

8 metrics

IPO shares offered 28,000,000 shares MiniMed common stock initial public offering

IPO price $20.00 per share MiniMed IPO price to the public

Over-allotment shares 4,200,000 shares 30-day underwriter option for additional MiniMed shares

Medtronic ownership post-IPO 90.03% MiniMed ownership upon IPO completion without over-allotment

Medtronic ownership with option 88.70% MiniMed ownership if over-allotment option exercised in full

Underwriter option period 30 days Window to purchase additional MiniMed shares

Trading start date March 6, 2026 Expected Nasdaq Global Select Market listing for MMED

Expected closing date March 9, 2026 Expected closing of MiniMed IPO

Market Reality Check

Price: $90.89 Vol: Volume 8,288,895 vs 20-da...

normal vol

$90.89 Last Close

Volume Volume 8,288,895 vs 20-day average 8,733,453, with relative volume at 0.95 ahead of this IPO news. normal

Technical Shares traded below the 200-day MA of 94.21 before the MiniMed IPO pricing update.

Peers on Argus

MDT was down 2.71% while key peers were mixed: SYK -1.76%, EW -0.65%, ZBH -1.06%...

MDT was down 2.71% while key peers were mixed: SYK -1.76%, EW -0.65%, ZBH -1.06%, PHG -1.13%, but BSX gained 1.81%. This mix points more to company-specific factors than a uniform sector move.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Investor conferences update	Neutral	-1.4%	CFO scheduled for fireside chats at two investor conferences in March.
Feb 25	Product launch EMEA	Positive	-0.1%	EMEA launch of MiniMed Go Smart MDI system with Simplera sensor integration.
Feb 24	MiniMed IPO roadshow	Neutral	-1.9%	MiniMed began IPO roadshow with 28M shares and 4.2M over-allotment option.
Feb 17	Q3 FY26 earnings	Positive	-3.1%	Reported $9.017B revenue, EPS beat, and reiterated FY26 guidance with solid growth.
Feb 17	Hugo RAS milestone	Positive	-3.1%	First U.S. commercial surgery using FDA-cleared Hugo robotic-assisted surgery system.

Pattern Detected

Recent history shows MDT shares often trading lower after both operational positives (Q3 beat, product launches) and MiniMed IPO steps, suggesting a pattern of skeptical or profit-taking responses to news.

Recent Company History

Over the last few weeks, Medtronic has reported several notable developments. On Feb 17, it posted strong Q3 FY26 results with revenue of $9.017B and reiterated guidance, yet the stock fell about 3.1%. The same day it announced the first U.S. commercial surgery using the Hugo RAS system, which also coincided with a similar decline. MiniMed’s IPO roadshow launch on Feb 24 and its EMEA MiniMed Go launch on Feb 25 preceded modest share pullbacks. Today’s IPO pricing continues this MiniMed separation storyline.

Market Pulse Summary

This announcement finalizes key terms of the MiniMed IPO, including 28,000,000 shares at $20 and Med...

Analysis

This announcement finalizes key terms of the MiniMed IPO, including 28,000,000 shares at $20 and Medtronic’s retained ownership of 90.03%–88.70%. It follows earlier updates on the roadshow and Medtronic’s strong Q3 FY26 results and Diabetes growth. Investors may watch how MiniMed trades on Nasdaq from March 6, 2026, the ultimate IPO proceeds mix between corporate uses and intercompany debt repayment, and how Medtronic’s strategy for its Diabetes business evolves post-offering.

Key Terms

initial public offering, nasdaq global select market, over-allotment option, underwriters, +4 more

8 terms

initial public offering financial

"today announced the pricing of its initial public offering (IPO) of 28,000,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

nasdaq global select market regulatory

"The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq)"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

over-allotment option financial

"30-day option to purchase up to 4,200,000 additional shares of common stock"

An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.

underwriters financial

"MiniMed has granted the underwriters a 30-day option to purchase up to 4,200,000"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

bookrunners financial

"Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley are acting as the active bookrunners"

Bookrunners are financial institutions or banks that lead the process of organizing and managing the sale of new securities, such as stocks or bonds, to investors. They coordinate the offering, determine the initial price, and ensure that the securities are sold efficiently, much like a conductor directs an orchestra to deliver a smooth performance. Their role matters to investors because they help ensure the offering is successful and fairly priced.

prospectus regulatory

"The offering will be made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

form s-1 regulatory

"A registration statement on Form S-1 relating to these securities has been filed"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

u.s. securities and exchange commission (sec) regulatory

"declared effective by, the U.S. Securities and Exchange Commission (SEC)."

The U.S. Securities and Exchange Commission (SEC) is the federal agency that writes and enforces rules for buying, selling and reporting information about stocks, bonds and other investments. Think of it as a referee and scoreboard operator: it protects investors by requiring companies to disclose accurate financial information and policing fraud, so investors can compare options and trust the markets are fair.

AI-generated analysis. Not financial advice.

GALWAY, Ireland and NORTHRIDGE, Calif., March 5, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026, under the symbol "MMED." The offering is expected to close on March 9, 2026, subject to customary closing conditions.

MiniMed has granted the underwriters a 30-day option to purchase up to 4,200,000 additional shares of common stock at the initial price to the public, less underwriting discounts and commissions. Upon completion of the IPO, Medtronic is expected to hold approximately 90.03% of MiniMed, or 88.70% if the underwriters exercise their over-allotment option in full. MiniMed intends to use a portion of the net proceeds from this offering for general corporate purposes. The remainder, if any, will be used to repay intercompany debt owed to Medtronic and as additional consideration to Medtronic for certain assets transferred to MiniMed in the separation.

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley are acting as the active bookrunners for the proposed offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and Piper Sandler are also acting as joint book running managers and BTIG and William Blair & Company, L.L.C. are acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com.

A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MiniMed

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO. Important factors that could cause actual results to differ materially from management's expectations include, without limitation: the satisfaction of customary closing conditions relating to the IPO; capital market risks; and the impact of general economic or industry conditions. There can be no guarantees that MiniMed or Medtronic will achieve the anticipated benefits of the IPO. The ability of MiniMed or Medtronic to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed or Medtronic, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside the control of MiniMed or Medtronic. For additional information about the factors that affect Medtronic's and MiniMed's businesses, please see their respective filings with the SEC. Each of Medtronic and MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

MiniMed Contacts

Janet Cho
Public Relations
+1-818-403-7028
Ryan Weispfenning 

Investor Relations
+1-763-505-4626 

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-announces-pricing-of-initial-public-offering-302706145.html

SOURCE MiniMed

FAQ

What did MiniMed announce about its IPO pricing and listing date (MMED)?

MiniMed priced its IPO at $20.00 per share for 28,000,000 shares. According to MiniMed, shares are expected to begin trading on Nasdaq on March 6, 2026, with the offering expected to close on March 9, 2026, subject to customary closing conditions.

How much ownership will Medtronic hold in MiniMed after the MMED IPO?

Medtronic is expected to hold approximately 90.03% ownership after the IPO. According to MiniMed, that stake would reduce to about 88.70% if underwriters exercise the full 30-day over-allotment option.

Will MiniMed use IPO proceeds to repay debt to Medtronic and for what other purposes?

MiniMed intends to use a portion of net proceeds for general corporate purposes and to repay intercompany debt. According to MiniMed, any remaining proceeds may also be used as additional consideration to Medtronic for assets transferred in the separation.

What is the size of the underwriters' option on the MiniMed (MMED) IPO?

Underwriters have a 30-day option to purchase up to 4,200,000 additional shares at the IPO price. According to MiniMed, this over-allotment option represents 15% of the initial 28,000,000-share offering and can affect final public float and ownership percentages.

Which banks are leading the MiniMed MMED IPO and how can investors get the prospectus?

Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are the active bookrunners. According to MiniMed, prospectus copies will be available from those firms' prospectus departments and distribution channels named in the offering announcement.